Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
International Journal of Rheumatic Diseases|May 9, 2017
Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysisAnna J Lomax, Helen M McGuire, Catriona McNeil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Metabolism: Clinical and Experimental|July 23, 2019
AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver diseaseNikolaos Nikolaou, Laura L Gathercole, Lea Marchand, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
International Journal of Radiation Oncology, Biology, Physics|November 20, 2015
MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast CancerHarriet E Gee, Francesca M Buffa, Adrian L Harris, et al.
The Lancet. Oncology|June 5, 2019
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trialIan Judson, James P Morden, Lucy Kilburn, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
JAMA Oncology|November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialPaolo A Ascierto, Georgina V Long, Caroline Robert, et al.
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
Pageof 4